Andere Sprachen Immutep ADR Nasdaq

Aktien

A2H8YL

US45257L1089

IMMP

Markt geschlossen - Nasdaq Andere Börsenplätze 22:00:00 02.05.2024			% 5 Tage	% 1. Jan.
2,69 ^USD	+3,46 %		+3,46 %	+12,08 %

02.05.	Immutep Limited berichtet über erste positive klinische Daten von Efti in Kombination mit Strahlentherapie und Checkpoint-Inhibitor aus Phase II-Studie bei Weichteilsarkomen	CI
02.05.	Immutep validiert erste Wirksamkeit von Immuntherapie-Medikament in Phase Zwei Krebs-Studie	MT

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Positive Initial Clinical Data Reported from Immutep’s Efti Combined with Radiotherapy and Checkpoint Inhibitor from Phase II Trial in Soft Tissue Sarcoma	02.05.
Immutep Limited Reports Positive Initial Clinical Data Reported from Efti Combined with Radiotherapy and Checkpoint Inhibitor from Phase II Trial in Soft Tissue Sarcoma	02.05.
Immutep Validates Initial Efficacy of Immunotherapy Medication in Phase Two Cancer Trial	02.05.
Immutep Quarterly Activities Report Q3 FY24	29.04.
Immutep Shows Positive Data in Trial to Treat Squamous Cell Cancers in Head, Neck	24.04.
Immutep Limited Announces Positive Preliminary Topline Results from TACTI-003 Cohort B	24.04.
Immutep Appoints Leading Research Institute to Conduct First-in-Human Phase I Study of IMP761	18.04.
Immutep Limited Appoints Leading Research Institute to Conduct First-In-Human Phase I Study of IMP761	18.04.
Wilsons - Adding Autoimmune to the indication list; Mtn Overweight, A$0.90 Tgt (Analysts: Dr Melissa Benson and Dr Shane Storey)	18.04.
Immutep Taps Center for Human Drug Research for IMP761 Human Clinical Trial	18.04.
Immutep : Appoints Leading Research Institute to Conduct First-in-Human Phase I Study of IMP76	18.04.
Immutep Receives Positive Feedback from the Spanish Medicines Agency for Upcoming TACTI-004 Registrational Trial in Metastatic Non-Small Cell Lung Cancer	17.04.
Immutep Limited Receives Positive Feedback from the Spanish Medicines Agency for Upcoming Tacti-004 Registrational Trial in Metastatic Non-Small Cell Lung Cancer	17.04.
Australian Shares Tick Down as US Fed Chair Flags Likely Rate Cut Delay	17.04.
Immutep Obtains Support from Spanish Health Agency for Efti Registrational Trial	17.04.
Immutep : Corporate Presentation	26.03.
Encouraging results for Immutep's cancer therapies	25.03.
Ladenburg Thalmann - Next Is Dose Optimization for BC Program; Reiterate Buy, $8.30 PT (Analyst: Ahu Demir, PhD)	06.03.
Wilsons - Dose it higher? Now an option; Mtn Overweight, A$0.90 Tgt (Analysts: Dr Melissa Benson and Dr Shane Storey)	05.03.
Immutep Announces First Clinical Data from 90mg Dosing of Efti	05.03.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Immutep ADR Nasdaq

Aktien

A2H8YL

US45257L1089

IMMP

Andere Sprachen

Filter